UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000048456
Receipt number R000055216
Scientific Title Effects of consumption of the food containing lactic acid bacteria on the intestinal environment in healthy Japanese subjects: a randomized, placebo-controlled, double-blind, parallel-group comparison study
Date of disclosure of the study information 2023/11/28
Last modified on 2023/11/28 14:10:48

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effects of consumption of the food containing lactic acid bacteria on the intestinal environment in healthy Japanese subjects

Acronym

Effects of consumption of the food containing lactic acid bacteria on the intestinal environment in healthy Japanese subjects

Scientific Title

Effects of consumption of the food containing lactic acid bacteria on the intestinal environment in healthy Japanese subjects: a randomized, placebo-controlled, double-blind, parallel-group comparison study

Scientific Title:Acronym

Effects of consumption of the food containing lactic acid bacteria on the intestinal environment in healthy Japanese subjects

Region

Japan


Condition

Condition

Healthy Japanese subjects

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To verify the effects of consumption of the food containing lactic acid bacteria on the intestinal environment in healthy Japanese subjects

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

1. Gut microbiota

Key secondary outcomes

1. The state of defecation (numbers of defecation days, defecation frequency, amount of defecation, stool shape, stool color, stool smell, and exhilarating feeling of defecation)

2. Organic acids and intestinal putrefactive products

3. The Japanese Version of the Constipation Assessment Scale Middle Term version (CAS-MT)

4. OSA sleep inventory MA version


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

YES

Dynamic allocation


Institution consideration

Institution is not considered as adjustment factor.

Blocking

YES

Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Duration: Two weeks
Test food: Tablet containing lactic acid bacteria
Administration: Take one tablet with water at any time during the day

*Daily dose should be taken within the day and not carried over to the next day.

Interventions/Control_2

Duration: Two weeks
Test food: Tablet not containing lactic acid bacteria
Administration: Take one tablet with water at any time during the day

*Daily dose should be taken within the day and not carried over to the next day.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

64 years-old >=

Gender

Male and Female

Key inclusion criteria

1. Japanese

2. Men or women

3. Subjects aged between 20 and 64

4. Healthy subjects

5. Subjects whose defecation frequency is three to five times per week

6. Subjects whose occupancy rate of Bifidobacterium is relatively low

Key exclusion criteria

Subjects (who/whose)
1.are undergoing medical treatment or have a medical history of malignant tumor, heart failure, and myocardial infarction
2.have a pacemaker or an implantable cardioverter defibrillator (ICD)
3.currently undergoing treatment for chronic disease such as arrhythmia, hepatopathy, nephropathy, cerebrovascular disorder, rheumatism, diabetes, dyslipidemia, hypertension
4.have chronic constipation
5.have other diseases that may significantly affect bowel movement, or who have a medical history of them
6.have asthma, or may develop asthma during this trial
7.occupancy rate of Lactobacillales order or Bifidobacterium at screening (before consumprion; Scr) is 0%
8.usually use foods containing rich in lactic acid bacteria, or lactic acid bacteria fortified health foods or medicines
9.usually use foods containing rich in Bacillus subtilis var. natto (B. natto), or B. natto fortified health foods or medicines
10.usually use medicines, health foods, "Foods for Specified Health Uses (FOSHU)," or "Foods with Functional Claims (FFC)" that may affect bowel movement / take ingredients affecting bowel movement (such as dietary fiber) fortified foods
11.usually use or take other FOSHU or FFC
12.currently taking medications (including herbal medicines) and supplements
13.are allergic to medicines and/or the test food related products
14.are day- and night- shift workers / work night multiple times during this trial
15.plan to go abroad during this trial
16.anthropometric measurements, physical examination values or laboratory values markedly deviate from the reference values at pre-consumption test
17.are pregnant, lactation, or planning to become pregnant during this trial
18.suffer from COVID-19
19.have been enrolled in other clinical trials within the last 28 days before the agreement to participate in this trial or plan to participate another trial during this trial
20.are judged as ineligible to participate in this study by the physician

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Tsuyoshi
Middle name
Last name Takara

Organization

Medical Corporation Seishinkai, Takara Clinic

Division name

Director

Zip code

141-0022

Address

9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan

TEL

03-5793-3623

Email

t-takara@takara-clinic.com


Public contact

Name of contact person

1st name Naoko
Middle name
Last name Suzuki

Organization

ORTHOMEDICO Inc.

Division name

R&D Department

Zip code

112-0002

Address

2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan.

TEL

03-3818-0610

Homepage URL


Email

nao@orthomedico.jp


Sponsor or person

Institute

ORTHOMEDICO Inc.

Institute

Department

Personal name



Funding Source

Organization

KAMEDA SEIKA CO., LTD.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor

Medical Corporation Seishinkai, Takara Clinic

Nerima Medical Association, Minami-machi Clinic

Name of secondary funder(s)



IRB Contact (For public release)

Organization

the ethical committee of the Takara Clinic, Medical Corporation Seishinkai

Address

9F Taisei Building, 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan.

Tel

03-5793-3623

Email

IRB@takara-clinic.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

医療法人社団盛心会 タカラクリニック (東京都)
Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan)

南町医院 (東京都)
Nerima Medical Association, Minami-machi Clinic (Tokyo, Japan)


Other administrative information

Date of disclosure of the study information

2023 Year 11 Month 28 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2022 Year 07 Month 20 Day

Date of IRB

2022 Year 07 Month 20 Day

Anticipated trial start date

2022 Year 07 Month 28 Day

Last follow-up date

2022 Year 11 Month 28 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2022 Year 07 Month 25 Day

Last modified on

2023 Year 11 Month 28 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000055216


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name